The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme as we advance to phase III trials. CT-388 is an important asset for unlocking the promise of our obesity pipeline, according to Roche, who added that the treatment is considered as a combination asset for petrelintide, an amylin analogue
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications that are effective treatment for patients with type 2 diabetes mellitus (T2DM) and weight control by stimulating insulin secretion, suppressing glucagon secretion, delaying gastric emptying and decreasing appetite. To investigate whether GLP-1RAs might have a positive impact in patients with knee OA, Zhu and colleagues analyzed data from a prospective, observational, multicenter study called the Shanghai Osteoarthritis Cohort
This means adults who are obese or overweightwith at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetesmay benefit from this new treatment
It can take anywhere from a few days to several weeks
Another direction has been to target multiple receptors involved in stimulating insulin production
